DGAP-News: Apricus Biosciences Granted Regulatory Meeting With FDA for Femprox(R) for the Treatment of Female Sexual Arousal Disorder
Apricus Biosciences, Inc.
21.05.2012 15:35
—————————————————————————
SAN DIEGO, 2012-05-21 15:35 CEST (GLOBE NEWSWIRE) —
Apricus Biosciences, Inc. (–Apricus Bio– or the –Company–) (Nasdaq:APRI)
(http://www.apricusbio.com) announced today that the United States (–U.S.–)
Food and Drug Administration (–FDA–) has granted the Company–s request for a
Type C meeting to obtain regulatory guidance from the agency for Femprox(r), the
Company–
